Roelien H. Enting

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

Martin J. van den Bent, Alba A. Brandes, Martin Taphoorn et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 738 citations

Neuro-oncology, Oncology, Single-agent Bevacizumab +10

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Brigitta G. Baumert, Monika E. Hegi, Martin J. van den Bent et al. · The Lancet Oncology · 2016 · 485 citations · Full text

Neuro-oncology, Glioma, Radiation Therapy +10

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge et al. · The Lancet · 2017 · 392 citations · Full text

Catnon Trial, Treatment Strategies, Radiation Therapy +13

Cognitive Rehabilitation in Patients With Gliomas: A Randomized, Controlled Trial

Karin Gehring, Margriet M. Sitskoorn, Chad M. Gundy et al. · Journal of Clinical Oncology · 2009 · 338 citations · Full text